Immune checkpoint inhibitor in pediatric melanoma : case report.
Inhibidor de punto de control inmunitario en melanoma pediátrico : reporte de caso.
Article Sidebar
PDF (Español (España))
FLIP
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Main Article Content
We document a 15-year-old girl who developed a stage IIID malignant melanoma on her left gluteal region. The patient underwent a local excision and sentinel lymph node biopsy, and then she was treated with adjuvant therapy with interferon, unfortunately the patient abandoned treatment, she resumed treatment four months later, and disease progression was detected, she received treatment with a immune checkpoint inhibitor and presented an unfavorable response, with disease progression. This case report highlights the clinical findings of this condition and presents controversies related to treatment with a immune checkpoint inhibitor in pediatric melanoma.
Downloads
Article Details
Indini A, Brecht I, Del Vecchio M, et al. Cutaneous melanoma in adolescents and young adults. Pediatr Blood Cancer. 2018;e27292.
Dean P, Bucevska M, Strahlendorf C, et al. Pediatric melanoma: A 35-year population-based review. Plast Reconstr Surg Glob Open. 2017;5(3):e1252.
Ferrari A, Bisogno G, Cecchetto G, et al. Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience. J Pediatr. 2014;164(2):375-82.
Larsen A, Jensen M, Krag C. Long-term survival after metastatic childhood melanoma. Plast Reconstr Surg Glob Open. 2014;2:e163.
Albino F, Wood B, Oh A, et al. A case of pediatric melanoma: treatment considerations in advanced disease. Plast Reconstr Surg Glob Open. 2015;3:e402.
Bernal L, Russi A, Lizarazo D, et al. Estrategias de adyuvancia en melanoma: actualización e implicaciones para la práctica. Rev. Cáncer de Piel. 2018;1(1):31-4.
Ceballos P, Ruiz R, Mihm M. Melanoma in children. N Engl J Med. 1995;332:656-62.
Rousi E, Koskivuo I, Kaarela O, et al. Clinical and pathological aspects of melanoma among children in Finland. Acta Derm Venereol 2016;96:718-20.
Paradela S, Fonseca E, Pita S. Prognostic factors for melanoma in children and adolescents. Cancer. 2010;116:4334-44.
Strouse J, Fears T, Tucker M, et al. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005;23(21):4735-41.
Kinsler V, O’Hare P, Bulstrode N. Melanoma in congenital melanocytic naevi. Br J Dermatol. 2017;176(5):1131-43.
Robert C, Long G, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-30.
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824-35.
Popat S. Hyperprogression with immunotherapy: is it real? Editorial. Cancer. 2019;125(8):1218-20.
Champiat S, Ferrara R, Massara C. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018;15(12):748-62.
Yilmaz M, Akovali B. Hyperprogression after nivolumab for melanoma: a case report. J Oncol Pharm Pract. 2019 May 8:1078155219845436.
Ji Z, Peng Z, Gong J. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. BMC Cancer. 2019;19:705.
Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non- small cell lung cancer treated with PD-1/PD- L1 inhibitors or with singleagent chemotherapy. JAMA Oncol. 2018;4(11):1543-52.
Borcoman E, Nandikolla A, Long G, et al. Patterns of response and progression to immunotherapy. American Society of Clinical Oncology Educational Book. 2018;38:169-78.
Popat V, Gerber D. Hyperprogressive disease: a distinct effect of immunotherapy? J Thorac Dis. 2019;11(Suppl 3):S262–5.
